Crude palm oil price is going to be RM1,500.00 in 2015

still drop

Hovid result not that good.

the affin research is on 11/08/2014. so is outdated for now. the price when it initiate is RM1.41

some fund is selling

either 10.80 or 12.00

will go down

warrant fv is 0.23

PETALING JAYA: Goldis Bhd has failed in its proposed takeover offer for IGB Corp Bhd, as it has only secured undertakings of 48.29% of shareholders, which is below the 50% mark required to make the offer unconditional.

Last month, Goldis had launched a takeover offer for IGB at RM2.88 per share on the condition it gets at least 50% acceptance.

The company had then said it already directly owned a 31.11% stake in IGB, while the persons acting in concert (PACs) with it collectively had 20.49%. Put together, it was anticipated that Goldis should be able to raise the group’s shareholding in IGB to 51.15%.

However, as at Aug 18, which was the last market day for acceptances of the proposed offer, the aggregate shareholding of the PACs was about 229.31 million IGB shares, or 17.18% of the company.





“Taking into account the direct shareholdings of Goldis of approximately 31.11% and the undertakings of the PACs to accept the proposed offer, the collective shareholdings of Goldis and the PACs are approximately 48.29%,” Goldis told Bursa Malaysia.

When Goldis first proposed the exercise on July 17, it said the rationale was to increase its direct stake in IGB to more than 50%.

Upon completion of the proposed offer, Goldis would be able to increase its consolidated net assets and net profit attributable to the company accordingly.

When the deal was first announced, analysts said that Goldis’ offer of RM2.88 cash per IGB share substantially undervalued the assets of the property development and investment company.

The consensus view was that minority shareholders were unlikely to accept the offer, given the low premium. Goldis’ offer represented a premium of only four sen, or 1.41%, over the pre-suspension price of IGB shares of RM2.84.

While one research house described the offer as “unfair and unreasonable”, another analyst said it was not a “serious offer”.

PublicInvest Research has estimated IGB’s assets to be worth at least RM8bil, or RM5.85 per share, and this too is made on a conservative valuation.

It said that Goldis’ offer valued IGB’s equity at RM3.84bil, which was only 48% of the estimated revalued net asset value of RM8bil of IGB.

The principal activities of IGB are investment holding and property development. Through its subsidiaries, IGB is involved in activities such as property development, property investment, malls and hotel operations.

Some 53% of IGB’s revenue contribution comes from property investment, while 32% comes from hotel operations and 10% from property development.

low is 4.95

6.56

6.78

6.98. still down

if buy oldtown than better buy BJFood also

BJFOOD-WA can go up to RM3.00

i just wonder what the company will do with it. i do nto see quek will really make the move

arab demand 16.00

see at 0.70

see at 2.00

will buy again if is drop below 1.00

for me sell a little. cash out

2.50 - 4.00 everybody guess. vincent tan counter everything can

2.00

1.98
fv for the warrant

Berjaya food buy the remainning starbulk. Parent is 2.34 warrant is 1.37. FV Warrant shall be 1.64

maybe igb will revise price ot 3.50 at least. too low

so have to buy goldis or igb

buy igb maybe will reach 3.50 on monday. maybe offer will revise

who know maybe offer revise

LOOK LIKE SOMETHING

something is going on

you still need to pay 1.10 if you want to accept the right
unless you sell the right at market which is 0.375

http://hovidonlinestore.com/

dreaming

5.26 still in down mode.

still like a snail.

2.00 to 8.00. huat...

8.00 is coming

the share price down due to thailand issue.

need to wait after the football

good. than your share will be more. than wait until 1.20 than buy again

salesman keep on changing. that;s what i heard

for pharma one year down the road shall be higher price than current. at least 20 - 25%

Maintain ADD but lift our price target to RM5.45/share
Overall, we remain positive on Bonia. While we maiantain our FY14-16 EPS
forecast, we have however raise our price target from RM4.00 to RM5.45 (ex-all
RM1.36), as we: 1) roll over our valution horizon to CY15 EPS; and 2) raise our
target multiple from 13x to 15x. We peg the stock at a higher target multiple in
view of the corporate exercise which would definitely boost the stock’s liquidity.
We reckon that Bonia’s low liquidity has been an impediment for investors’
seeking to invest in the stock (average 6 month volume, 120,000 shares). With
an upside potential of 11%, we maintain our ADD recommendation on Bonia.
Key risk to our view is a sharp slowdown in regional consumer spending.

Maintain ADD but lift our price target to RM5.45/share
Overall, we remain positive on Bonia. While we maiantain our FY14-16 EPS
forecast, we have however raise our price target from RM4.00 to RM5.45 (ex-all
RM1.36), as we: 1) roll over our valution horizon to CY15 EPS; and 2) raise our
target multiple from 13x to 15x. We peg the stock at a higher target multiple in
view of the corporate exercise which would definitely boost the stock’s liquidity.
We reckon that Bonia’s low liquidity has been an impediment for investors’
seeking to invest in the stock (average 6 month volume, 120,000 shares). With
an upside potential of 11%, we maintain our ADD recommendation on Bonia.
Key risk to our view is a sharp slowdown in regional consumer spending.

5.03

5.15

Wait for announcement

Edited CIMB Research
We begin coverage of the stock with an Add rating and target price of
RM6.50, based on 19.2x CY15 P/E, a 20% premium over its 3-year average
forward P/E in view of its strong EPS CAGR of 28.1% for FY13-16. We like
its strong market positioning and manufacturing growth potential.
Stronger earnings and higher dividends are potential catalysts, in
our view.

Under-researched stock with strong earnings growth Pharmaniaga is an under-researched stock, in our view, as it is covered by only one broker currently, according to Bloomberg. However, we think that
Pharmaniaga warrants a closer look by investors.
The group is the largest pharmaceutical stock in Malaysia by market cap. It is well positioned to tap the rising healthcare spending in Malaysia via its
Concession Agreement with MOH. The group’s manufacturing division could
also benefit from the patent cliff, which allows it to launch more products in the next few years. We expect the manufacturing division to be the main thrust of earnings growth as in-house products have much higher profit margins vis-à-vis distributing third-party products.

are you sure. proof